

Special Issue

Personalized Medicine in Spondyloarthritis

Message from the Guest Editor

Important advances in the understanding of SpA have been made in the area of classification criteria, significantly improving the approach to these diseases and the identification of patients in early stages of the disease. Numerous studies have elucidated the immune mechanisms underlying specific clinical manifestations of the disease, opening the way to new and more personalized therapeutic approaches. In particular, new and more specific treatments promise to make feasible treat-to-target and drug-free remission in SpA, which were once impossible objectives. Although the diagnostic delay in SpA is still considerable, the increased awareness and insights into diagnosis at early stages of the disease are contributing to improving its management. The present Special Issue aims to deepen the knowledge of SpA from bench to bedside, providing a broad update on the pathophysiological, diagnostic, and therapeutic aspects of the disease.

Guest Editor

Prof. Dr. Codrina Ancuta

Rheumatology Department, University of Medicine and Pharmacy
"Grigore T Popa", 700115 Iasi, Romania

Deadline for manuscript submissions

closed (15 September 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/156426

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).